⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374145 | 0.78 | THRB (0.32) | — | |
| SCHEMBL15765884 | 0.78 | HSD17B10 (0.40) | — | |
| SCHEMBL12575280 | 0.78 | KDM4E (0.37) | — | |
| SCHEMBL127129 | 0.77 | — | — | |
| SCHEMBL12371277 | 0.76 | — | — | |
| SCHEMBL248637 | 0.76 | — | — | |
| SCHEMBL248636 | 0.76 | — | — | |
| SCHEMBL2830350 | 0.75 | — | — | |
| SCHEMBL28178517 | 0.75 | — | — | |
| SCHEMBL11451788 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | claimed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | claimed |
| EP-3670515-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-10597382-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | claimed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | claimed |
| US-10081639-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-09-25 | — | — | US | claimed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | claimed |
| US-9856249-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2018-01-02 | — | — | US | claimed |
| EP-2806875-B1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | claimed |
| US-9346785-B2 | Process for making HCV protease inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | claimed |
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | claimed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20040157787-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003097659-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |